## CDE Notice of Copyright 6 Minute Walk Test

Availability	Freely available at this website: <u>6 Minute Walk Test</u>
	The protocol is freely available here: <u>6 Minute Walk Test Protocol</u>
Classification	Supplemental - Highly Recommended: Sickle Cell Disease (SCD) *Recommendations on Use: Indicated for studies targeted at walking function where the intended population is less severely impaired (i.e., AIS D) and may be able to walk 6 minutes. Consider a shorter test (i.e., 2 Minute Walk Test) for patients with more severe injuries or less endurance.
Short Description of Instrument	<ul> <li>Background: This test was originally developed for use in patients with cardiopulmonary disease, but has since been used in a variety of neurological conditions including MS. The 6-minute walk test (6MWT) measures the distance a patient can quickly walk on a flat, hard surface in a period of 6 minutes (the 6MWD). This evaluates the global and integrated responses of all the systems involved during exercise, including pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, blood, neuromuscular units, and muscle metabolism. The 6MWT does not provide specific information on the function of each of the different organs and systems involved in exercise, or the mechanism of exercise limitation as is possible with maximal cardiopulmonary exercise testing. The self-paced 6MWT assesses the submaximal level of functional capacity. Most patients do not achieve maximal exercise capacity during the 6MWT; instead, they choose their own intensity of exercise and can stop and rest during the test. However, because most activities of daily living are performed at submaximal levels of exercise level for daily physical activities.</li> <li>Construct measured: Walking speed</li> <li>Generic vs. disease specific: Generic</li> <li>Means of administration: Administered in-person by a trained examiner.</li> <li>Intended respondent: Patient</li> </ul>
Comments/Special Instructions	<b>Administration:</b> Administration time will vary depending on the patient's ability. Total administration time should be approximately 6 minutes.

Rationale/Justification	<b>Strengths/Weaknesses:</b> Sources of variability include the following: Factors reducing the 6MWD - Shorter height, Older age, Higher body weight, Female sex, Impaired cognition, A shorter corridor (more turns), Pulmonary disease (COPD, asthma, cystic fibrosis, interstitial lung disease), Cardiovascular disease (angina, MI, CHF, stroke, TIA, PVD, AAI), Musculoskeletal disorders (arthritis, ankle, knee, or hip injuries, muscle wasting, fatigue, etc.); Factors increasing the 6MWD - Taller height (longer legs), Male sex, High motivation, A patient who has previously performed the test, Medication for a disabling disease taken just before the test, Oxygen supplementation in patients with exercise-induced hypoxemia.
Scoring and Psychometric Properties	<b>Scoring:</b> Record the number of laps from the counter (or tick marks on the worksheet). Record the additional distance covered (the number of meters in the final partial lap) using the markers on the wall as distance guides. Calculate the total distance walked, rounding to the nearest meter, and record it on the worksheet. Most 6MWTs will be done before and after intervention, and the primary question to be answered after both tests have been completed is whether the patient has experienced a clinically significant improvement. Assistive devices can be used but should be recorded at each test. <b>Psychometric Properties:</b> The 6-min walk has good test-retest reliability in older populations (.88 < $R$ < .94). particularly when a practice trial preceded the test trial. Convergent validity of the 6-min walk was demonstrated by its moderate correlation (.71 < r < .82) with treadmill performance. Construct validity was assessed by determining the ability of the test to detect differences between different age and activity level groups. As expected, walking scores decreased significantly across decades and were significantly lower for low-active subjects compared to high-active subjects. There was a moderate relationship between 6-min walk scores and self-reported functional ability. It was concluded that the 6-min walk can be used to obtain reasonably reliable and valid measures of physical endurance in older adults and that it moderately reflects overall physical functional performance. In healthy children, the 6-min walk test is a reliable and valid functional test for assessing exercise tolerance.
References	Balke B. A simple field test for the assessment of physicial fitness. Rep Civ Aeromed Res Inst US. 1963;53:1-8.

Butland RJ, Pang J, Gross ER, Woodcock AA, Geddes DM. Two-, six-, and 12-minute walking tests in respiratory disease. Br Med J (Clin Res Ed). 1982;284(6329):1607-1608.

Li AM, Yin J, Yu CCW, Tsang T, So HK, Wong E, Chan D, Hon EKL, Sung R. The six-minute walk test in healthy children: reliability and validity. European Respiratory Journal. 2005; 25: 1057-1060.

Society AT. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111-117.

## Sickle Cell Specific References:

Anthi A, Machado RF, Jison ML, et al. Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. *Am J Respir Crit Care Med.* 2007;175(12):1272-1279.

Brousse V, Pondarre C, Arnaud C, et al. One-Fifth of Children with Sickle Cell Anemia Show Exercise-Induced Hemoglobin Desaturation: Rate of Perceived Exertion and Role of Blood Rheology. *J Clin Med.* 2020;9(1).

Campbell A, Minniti CP, Nouraie M, et al. Prospective evaluation of haemoglobin oxygen saturation at rest and after exercise in paediatric sickle cell disease patients. *Br J Haematol.* 2009;147(3):352-359.

Connes P, Machado R, Hue O, Reid H. Exercise limitation, exercise testing and exercise recommendations in sickle cell anemia. *Clin Hemorheol Microcirc*. 2011;49(1-4):151-163.

Dedeken L, Chapusette R, Le PQ, et al. Reduction of the six-minute walk distance in children with sickle cell disease is correlated with silent infarct: results from a cross-sectional evaluation in a single center in Belgium. *PLoS One.* 2014;9(9):e108922.

Gordeuk VR, Minniti CP, Nouraie M, et al. Elevated tricuspid regurgitation velocity and decline in exercise capacity over 22 months of follow up in children and adolescents with sickle cell anemia. *Haematologica*. 2011;96(1):33-40.

Hostyn SV, Carvalho WB, Johnston C, Braga JA. Evaluation of functional capacity for exercise in children and adolescents with sickle-cell disease through the six-minute walk test. *J Pediatr (Rio J)*. 2013;89(6):588-594.

Mockesch B, Charlot K, Jumet S, et al. Micro- and macrovascular function in children with sickle cell anaemia and sickle cell haemoglobin C disease. *Blood Cells Mol Dis.* 2017;64:23-29.

Ohara DG, Ruas G, Walsh IA, Castro SS, Jamami M. Lung function and six-minute walk test performance in individuals with sickle cell disease. *Braz J Phys Ther.* 2014;18(1):79-87.

Vieira AK, Alvim CG, Carneiro MC, Ibiapina CD. Pulmonary function in children and adolescents with sickle cell disease: have we paid proper attention to this problem? *J Bras Pneumol.* 2016;42(6):409-415.

Waltz X, Romana M, Lalanne-Mistrih ML, et al. Hematologic and hemorheological determinants of resting and exercise-induced hemoglobin oxygen desaturation in children with sickle cell disease. *Haematologica*. 2013;98(7):1039-1044.